Sun Life Financial 2Q Earnings Slip
By Connor Hart
Sun Life Financial posted a slightly lower second-quarter profit, while it announced plans to renew its stock buyback program.
The Toronto-based insurance company posted a profit of C$646 million, equivalent to $470 million, in the second quarter, compared to C$660 million in last year's quarter. On a per-share basis, the company posted a profit of C$1.11, compared to C$1.12 last year.
Adjusted per-share earnings were C$1.72, compared to C$1.57 in the previous year.
Sun Life said it will renew its stock buyback program to purchase 15 million shares, or about 2.6% of its outstanding stock.
The buyback, expected to start by Aug. 29, is part of the company's overall capital management strategy.
The purchases will generally be made through the facilities of the Toronto Stock Exchange, or other Canadian stock exchanges, at prevailing market rates. Subject to regulatory approval, purchases may also be made by way of private agreements or exemption orders, generally at a discount to the prevailing market price, the company said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 12, 2024 18:09 ET (22:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks